molecules of the month


potent, selective, Q2W IV CD73 inhibitor

completed Ph. I in HV, in dev. for cancer imm.

from opt. of known nucleotide CD73 inh.

J. Med. Chem., Jul. 20, 2020

Arcus Biosciences, Hayward, CA

Structure of AB680, a potent small-molecule inhibitor of CD73
1 min read

AB680 is a potent (5 pM) and selective inhibitor of CD73, a nucleotidase that metabolizes AMP to immunosuppressive extracellular adenosine. AB680 is intended to be used in combination with checkpoint inhibitor biologics in cancer immunotherapy, and has a PK profile for biweekly (Q2W) IV dosing in humans based on a Ph. I study in healthy volunteers.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: